- Home
- GKOS
GKOS
Glaukos Corporation
as 04-18-2025 1:36pm EST
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
| Founded: | 1998 | Country: | United States |
| Employees: | 995 | City: | ALISO VIEJO |
| Market Cap: | 5.1B | IPO Year: | 2015 |
| Target Price: | $155.00 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $77.91 - $163.71 | Next Earning Date: | 04-30-2025 |
| Revenue: | $383,481,000 | Revenue Growth: | 21.85% |
| Revenue Growth (this year): | 27.84% | Revenue Growth (next year): | 27.99% |
Stock Insider Trading Activity of Glaukos Corporation (GKOS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Thurman Alex R. | GKOS | SVP & CHIEF FINANCIAL OFFICER | Mar 25 '25 | Sell | $107.38 | 1,520 | $162,398.58 | 53,892 | |
| Foley Mark J | GKOS | Director | Feb 26 '25 | Sell | $120.72 | 20,687 | $2,497,334.64 | 54,249 | |
| Navratil Tomas | GKOS | CHIEF DEVELOPMENT OFFICER | Feb 14 '25 | Sell | $147.14 | 3,416 | $502,630.24 | 72,437 |
Latest Glaukos Corporation News
GKOS Breaking Stock News: Dive into GKOS Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Glaukos Announces the Release of its 2024 Sustainability Report
Argus Research
4 days ago
GKOS: Raising target price to $99.00
MT Newswires
8 days ago
Truist Cuts Price Target on Glaukos to $140 From $185, Keeps Buy Rating
Zacks
9 days ago
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?
Business Wire
10 days ago
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
Argus Research
11 days ago
GKOS: Lowering target price to $86.00
Insider Monkey
11 days ago
What Makes Glaukos Corporation (GKOS) a Compelling Stock?
Argus Research
18 days ago
GKOS: Rating increased to a HOLD
Compare GKOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GKOS Glaukos Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.